Chimerix Inc. (NASDAQ:CMRX) saw unusually-high trading volume on Wednesday . Approximately 507,772 shares traded hands during trading, a decline of 5% from the previous session’s volume of 532,702 shares.The stock last traded at $5.01 and had previously closed at $4.76.

CMRX has been the subject of a number of recent research reports. Piper Jaffray Cos. set a $12.00 price objective on Chimerix and gave the stock a “buy” rating in a research report on Thursday, August 18th. Zacks Investment Research upgraded Chimerix from a “hold” rating to a “buy” rating and set a $4.75 price objective for the company in a research report on Wednesday, August 10th. FBR & Co dropped their price objective on Chimerix from $9.00 to $8.00 and set a “mkt perform” rating for the company in a research report on Tuesday, August 9th. Finally, JPMorgan Chase & Co. restated a “hold” rating and issued a $7.00 price target on shares of Chimerix in a report on Tuesday, August 9th. Two research analysts have rated the stock with a sell rating, ten have given a hold rating, two have issued a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Hold” and an average price target of $15.72.

The stock’s market cap is $210.27 million. The firm’s 50-day moving average is $4.21 and its 200-day moving average is $4.89.

Chimerix (NASDAQ:CMRX) last announced its earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.39) EPS for the quarter, beating the consensus estimate of ($0.51) by $0.12. The company had revenue of $1.80 million for the quarter, compared to analysts’ expectations of $1.98 million. On average, equities research analysts anticipate that Chimerix Inc. will post ($1.78) earnings per share for the current fiscal year.

In related news, CEO M Michelle Berrey bought 13,188 shares of Chimerix stock in a transaction dated Friday, June 24th. The stock was acquired at an average cost of $3.69 per share, with a total value of $48,663.72. Following the completion of the acquisition, the chief executive officer now directly owns 258,821 shares in the company, valued at approximately $955,049.49. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Ernest Mario bought 50,000 shares of Chimerix stock in a transaction dated Friday, June 24th. The shares were bought at an average cost of $3.70 per share, with a total value of $185,000.00. Following the completion of the acquisition, the director now owns 381,440 shares of the company’s stock, valued at $1,411,328. The disclosure for this purchase can be found here.

Other large investors recently made changes to their positions in the company. Trexquant Investment LP increased its stake in shares of Chimerix by 453.5% in the fourth quarter. Trexquant Investment LP now owns 131,184 shares of the biopharmaceutical company’s stock valued at $1,174,000 after buying an additional 107,484 shares in the last quarter. Jennison Associates LLC raised its position in Chimerix by 67.9% in the fourth quarter. Jennison Associates LLC now owns 1,273,779 shares of the biopharmaceutical company’s stock valued at $11,400,000 after buying an additional 515,029 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. raised its position in Chimerix by 5.1% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 141,181 shares of the biopharmaceutical company’s stock valued at $1,264,000 after buying an additional 6,847 shares during the last quarter.

Chimerix, Inc (Chimerix) is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing oral antivirals. The Company, based on its lipid conjugate technology, has developed its lead compound, brincidofovir (BCV, CMX001), which is in Phase III clinical development.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.